Physicians Discuss Modifying Use of CDK4/6 Inhibitors in ER+/HR+ Metastatic Breast Cancer
September 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.
Debating When to Switch TKIs and How to Ensure Patient Adherence in CML
September 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.
Bryce Reviews PARP Inhibitor Combination Trials in Prostate Cancer
September 27th 2023During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.
Identifying the Role of Targeted Therapy in KRAS-Mutated NSCLC
September 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the use of sotorasib and adagrasib for patients with KRAS-mutated non–small cell lung cancer including those with brain metastases.
Atkins Assesses the Differences Between Immunotherapy Strategies in Advanced Melanoma
September 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with participants what factors influence the choice of first-line immunotherapy for a patient with BRAF–wild-type metastatic melanoma.
Pemmaraju Discusses Development of Targeted Therapy for BPDCN
September 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid dendritic cell neoplasm.
Salani Reviews Options for a Patient With Metastatic Endometrial Cancer
September 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.
Phillips Discusses Treatment Options for Early-Relapsed DLBCL
September 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tycel J. Phillips, MD, and participants discussed treatment options for a patient with diffuse large B-cell lymphoma who progressed after 8 months on first-line therapy and prefers to receive outpatient therapy.
Physicians Compare Platinum Rechallenge With Other Second-Line Options in ES-SCLC
September 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed with participants how they would treat a patient with small cell lung cancer after prior treatment with carboplatin plus etoposide.
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.
Traina Reviews Current Data for Antibody-Drug Conjugates in Breast Cancer
September 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.
Teclistamab Toxicities Highly Manageable in R/R Multiple Myeloma
September 19th 2023In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.
Analyzing Therapeutic Sequencing in Metastatic Prostate Cancer
September 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshi Alumkal, MD, discussed selection of next-line therapy for a patient with metastatic castration-resistant prostate cancer who stopped docetaxel after 4 cycles.
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
September 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.
Survivorship Care “Should Be Considered From the Moment of Diagnosis”
September 17th 2023In an interview with Targeted Oncology™, Alicia K. Morgans, MD, MPH, discussed how the survivorship program at Dana-Farber Cancer Institute helps patients with cancer and ways to incorporate aspects of a survivorship program into more academic and community institutions.
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
September 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.
Role of Tolerability in Using Immunotherapy for Metastatic Melanoma
September 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, and other physicians discussed which patients are more challenging when it comes to tolerating dual immunotherapy as frontline therapy for metastatic melanoma. This is the second of 2 articles based on this event.